乳腺癌前哨淋巴结活检规范化操作指南（2022精要版）

乳腺癌是女性最常见的恶性肿瘤,区域淋巴结状况作为重要的预后指标,可指导患者的淋巴结分期,并对后续治疗策略产生影响。前哨淋巴结活检术（sentinel lymph node biopsy,SLNB）标志着乳腺癌淋巴结外科处理进入微创时代,但其安全有效替代腋窝淋巴结清扫术应建立在规范化操作前提下。中国抗癌协会乳腺癌专业委员会组织业内专家依据循证医学方法制定《乳腺癌前哨淋巴结活检规范化操作指南》,内容涉及SLNB适应证、示踪剂选择与应用、组织标本处理、腋窝SLNB、新辅助治疗与SLNB、内乳SLNB。本指南将为乳腺癌相关医务工作者的临床实践提供有益指导和参考。 

Guidelines for standardized practice of sentinel lymph node biopsy in breast cancer (2022 abridged version)

Breast cancer is the most common malignant tumor in women. Regional lymph node status is an important prognostic indicator that guides staging of tumors and influences application of adjuvant therapy. Minimally invasive lymph node surgery in breast cancer begins with sentinel lymph node biopsy (SLNB), which is established based on the premise of a standardized operation as a safe and effective replacement for axillary lymph node dissection. The Committee of Breast Cancer Society of China Anti-Cancer Association invited authoritative experts nationwide to participate in the preparation of the Guidelines for Standardized Practice of Sentinel Lymph Node Biopsy in Breast Cancer based on evidence-based medicine, which focuses on the indications for SLNB, tracer selection and application, tissue specimen processing, axillary SLNB, neoadjuvant therapy and SLNB, and internal mammary SLNB. The guideline aims to provide the most effective references for practitioners to achieve the best outcomes for patients with breast cancer.